Slide 1 of 1 
Equine Erythropoietin (EPO) ELISA
- Catalog Number:
- DIY1146E
- Availability:
- In stock
- Application:
- ELISA
- 100% Homology:
- Equus caballus (horse), Equus przewalskii (Przewalski's horse)
Components
| Usage | Quantity | Component | Size |
|---|---|---|---|
| Detection Antibody | 50 µg | KPB1145E-050 | |
| Standard | 5 µg | RP0932E-005 | |
| Capture Antibody | 100 µg | KP1144E-100 | 1 Pack (<= 10 Plates) |
| Capture Antibody | 100 µg X 2 | KP1144E-100 | 1 Pack (<= 20 Plates) |
- The Equine EPO (Erythropoietin) ELISA is designed for the quantitative measurement of EPO in cell culture supernatants from horses and can also be used to measure EPO in a wide variety of biological sample types reported in the literature, including serum, plasma, whole blood, and tissue lysates from organs such as kidney, liver, and spleen, supporting a broad range of hematology, physiology, and translational research applications. EPO is a glycoprotein hormone primarily produced by renal interstitial fibroblasts and, to a lesser extent, the liver, and it plays a central role in stimulating erythroid progenitor cell proliferation and differentiation, regulating red blood cell production, and maintaining oxygen homeostasis. In the equine animal model, EPO is widely studied in the context of anemia, hypoxia, blood production, and regenerative medicine, where its expression reflects erythropoietic activity and oxygen-sensing mechanisms. Measurement of EPO provides valuable insight into hematopoietic function, disease progression, and the efficacy of therapeutic interventions targeting anemia or hypoxia. Reported measurements of equine EPO have detected basal serum and plasma levels of approximately 5-50 mIU/mL, with elevated levels-often 50-400 mIU/mL-following hypoxic challenge, blood loss, or pharmacological stimulation, and measurable expression has also been observed in tissue lysates from kidney and liver under stress or regenerative conditions. The kit contains a capture antibody, detection antibody, and recombinant protein standard for assay development, and these antibodies have been validated to function together in an ELISA format using the provided standard. While the kit is optimized for cell culture supernatants, minor modifications to the protocol may be required when measuring EPO in other sample types to ensure optimal sensitivity and accuracy. Optimal buffers, antibody concentrations, incubation times, temperatures, and assay conditions have not been predetermined, allowing researchers to further adjust assay parameters based on their specific sample type and experimental requirements. The quantities of kit components are not matched, and individual components may be purchased separately. This product is for research use only and is manufactured in the USA.
| Storage Conditions | 2°C to 8°C or -20°C |
| Country Of Origin | USA |
- Equine Erythropoietin (EPO) is a glycoprotein hormone belonging to the type I cytokine family that regulates erythropoiesis, the production of red blood cells. In horses (Equus caballus), erythropoietin is produced primarily by peritubular interstitial cells in the kidney, with smaller amounts synthesized in the liver, in response to hypoxia or reduced oxygen-carrying capacity of the blood. Equine EPO binds to the erythropoietin receptor (EPOR) on erythroid progenitor cells in the bone marrow, activating intracellular signaling pathways such as JAK2-STAT5, PI3K-AKT, and MAPK, which promote the survival, proliferation, and differentiation of erythroid precursor cells into mature red blood cells. In equine physiology, erythropoietin plays a crucial role in maintaining adequate oxygen delivery to tissues, which is particularly important for athletic performance and endurance in horses. Dysregulation of EPO production can contribute to anemia associated with chronic disease or kidney dysfunction. Horses are also used as comparative models for studying exercise physiology and erythropoiesis, and research on equine erythropoietin has contributed to understanding red blood cell regulation during intense exercise, hypoxia, and blood disorders, as well as the detection of recombinant EPO misuse in equine sports.
Please choose a size to see price
RELATED MEDIA
